All In Biotech

Drug Trial Radar · NCT03253263

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 295 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

295

Actual

Start

May 9, 2019

Primary completion

Jul 31, 2026

Study completion Jan 21, 2028

Sponsor

Lead sponsor
OHB Neonatology Ltd.Industry
Sponsor type
Industry
First posted
Aug 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 hours, up to 24 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.

Conditions

  • Bronchopulmonary Dysplasia
  • Chronic Lung Disease of Prematurity
  • Intraventricular Hemorrhage
  • Retinopathy of Prematurity (ROP)

Interventions

  • OHB-607Drug

    Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in the incidence of severe Bronchopulmonary Dysplasia (BPD) at 36 weeks (±3 days) Postmenstrual Age (PMA), or death at or before 36 weeks PMA, whichever comes first as compared to the SNC group.Time frame: Baseline through 36 weeks postmenstrual age (PMA)

Locations

62 sites in 13 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Children's Hospital of Orange County

    California City, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • US Davis

    Sacramento, California

  • Jackson Memorial Hospital

    Miami, Florida

  • Tampa General Hospital

    Tampa, Florida

  • University of Illinois at Chicago

    Chicago, Illinois

  • Riley Hospital for Children

    Indianapolis, Indiana

  • Memorial Hospital of South Bend

    South Bend, Indiana

  • University of Louisville Hospital

    Louisville, Kentucky

  • Ochsner Baptist Medical Center

    New Orleans, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Children's Minnesota - Children's Hospital and Clinics - St. Paul

    Saint Paul, Minnesota

  • Children's Minnesota - Children's Hospital and Clinics

    Saint Paul, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • University of Rochester

    Rochester, New York

  • Maria Fareri Children's Hospital

    Valhalla, New York

  • Oklahoma Children's Hospital - PIN

    Oklahoma City, Oklahoma

  • Medical University of South Carolina Children Hospital

    Charleston, South Carolina

  • Texas Children's Hospital

    Houston, Texas

  • UT Health Science Center

    San Antonio, Texas

  • UVA Children's Hospital

    Charlottesville, Virginia

  • Virginia Commonwealth University - Children's Hospital of Richmond at VCU

    Richmond, Virginia

  • Royal Women's Hospital

    Parkville, Australia

  • Mater Misericordiae Limited

    South Brisbane, Australia

  • Royal Hospital for Women

    Randwick, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Sainte Justine Hospital

    Montreal, Quebec, Canada

  • Oulun Yliopistollinen Sairaala

    Oulu, Finland

  • Klinikum Nürnberg

    Nuremberg, Germany

  • Universitatsklinikum Leipzig

    Leipzig, Saxony, Germany

  • Cork University Maternity Hospital

    Cork, Wilton, Ireland

  • Azienda Ospedaliero-Universitaria Careggi SOD Neonatologia e Terapia Intensiva Neonatale

    Florence, Italy

  • Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e

    Genova, Italy

  • Presidio Ospedaliero Di Treviso Ca' Foncello

    Treviso, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • Azienda Ospedaliera Di Padova

    Padova, Veneto, Italy

  • Showa Medical University Hospital

    Tokyo, Japan

  • National Center for Child Health and Development

    Tokyo, Japan

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.